Singapore markets close in 7 hours 32 minutes

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.50+0.38 (+4.68%)
At close: 04:00PM EDT
8.58 +0.08 (+0.94%)
After hours: 07:15PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.51B
Enterprise value 1.83B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)5.50
Price/book (mrq)56.59
Enterprise value/revenue 6.74
Enterprise value/EBITDA -12.70

Trading information

Stock price history

Beta (5Y monthly) 2.03
52-week change 3-47.56%
S&P500 52-week change 3-13.21%
52-week high 318.00
52-week low 37.61
50-day moving average 39.53
200-day moving average 311.62

Share statistics

Avg vol (3-month) 33.03M
Avg vol (10-day) 32.84M
Shares outstanding 5188.45M
Implied shares outstanding 6N/A
Float 8169.85M
% held by insiders 11.03%
% held by institutions 185.57%
Shares short (14 Mar 2023) 430.81M
Short ratio (14 Mar 2023) 48.05
Short % of float (14 Mar 2023) 418.31%
Short % of shares outstanding (14 Mar 2023) 416.35%
Shares short (prior month 14 Feb 2023) 426.99M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022


Profit margin -91.25%
Operating margin (ttm)-54.81%

Management effectiveness

Return on assets (ttm)-16.30%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)270.83M
Revenue per share (ttm)1.46
Quarterly revenue growth (yoy)68.70%
Gross profit (ttm)10.94M
Net income avi to common (ttm)-247.12M
Diluted EPS (ttm)-1.41
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)424.31M
Total cash per share (mrq)2.25
Total debt (mrq)741.45M
Total debt/equity (mrq)N/A
Current ratio (mrq)4.89
Book value per share (mrq)-1.57

Cash flow statement

Operating cash flow (ttm)-161.85M
Levered free cash flow (ttm)-142.33M